ЛЕЧЕНИЕ БРОНХИАЛЬНОЙ АСТМЫ И ЕЕ ОБОСТРЕНИЙ: СТАНДАРТИЗОВАННЫЕ КОНЕЧНЫЕ ПОКАЗАТЕЛИ ДЛЯ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ ПО АСТМЕ И КЛИНИЧЕСКОЙ ПРАКТИКИ.ОФИЦИАЛЬНЫЙ ДОКУМЕНТ АТО / ЕРО. ЧАСТЬ 2


https://doi.org/10.18093/0869-0189-2011-0-2-9-40

Полный текст:


Аннотация

Источник: Reddel H.K., Taylor D.R., Bateman E.D. et al. An Official American Thoracic Society / European Respiratory Society Statement: Asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 2009; 180: 59–99.


Список литературы

1. Woolcock A., Rubinfeld A.R., Seale J.P. et al. Thoracic Society of Australia and New Zealand. Asthma management plan, 1989. Med. J. Aust. 1989; 151: 650–653.

2. National Heart Lung and Blood Institute. International consensus report on diagnosis and treatment of asthma. Eur. Respir. J. 1992; 5: 601–641.

3. Rosi E., Ronchi M.C., Grazzini M. et al. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J. Allergy Clin.Immunol. 1999; 103: 232–237.

4. Crimi E, Spanevello A, Neri M. et al. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am. J. Respir. Crit. Care Med.1998; 157: 4–9.

5. National asthma education and prevention program expert panel report: 2. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart Lung and Blood Institute; 1997.

6. Taylor D.R., Bateman E.D., Boulet L.-P. et al. A new perspective on concepts of asthma severity and control. Eur. Respir. J. 2008; 32: 545–554.

7. Schünemann H.J., Jaeschke R., Cook D.J. et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am. J. Respir Crit. Care Med. 2006; 174:605–614.

8. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2008 [Accessed June 2008].Available from: www.ginasthma.com

9. National Heart Lung and Blood Institute National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007 [Accessed June 2008]. Available from:http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm

10. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am. J. Respir.

11. Crit. Care Med. 2000; 162: 2341–2351.

12. Lemiere C., Bai T., Balter M. et al. Adult asthma consensus guidelines update 2003. Can. Respir. J. 2004; 11: 9A–18A.

13. Lane S., Molina J., Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir. Med. 2006; 100: 434–450.

14. Pauwels R.A., Lofdahl C.-G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337: 1405–1411.

15. Jorgensen I.M., Jensen V.B., Bulow S. et al. Asthma mortality in the Danish child population: risk factors and causes of asthma death. Pediatr. Pulmonol. 2003; 36: 142–147.

16. O’Byrne P., Cuddy L., Taylor D.W. et al. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. Can. Respir. J. 1996; 3: 169–175.

17. O’Byrne P.M., Barnes P.J., Rodriguez-Roisin R. et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am. J. Respir.Crit. Care Med. 2001; 164: 1392–1397.

18. Plaza V., Serrano J., Picado C. et al. Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma. Eur. Respir. J. 2002; 19: 846–852.

19. Romagnoli M., Caramori G., Braccioni F. et al. Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin.Exp. Allergy 2007; 37: 552–557.

20. Tattersfield A.E., Postma D.S., Barnes P.J. et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am. J.Respir. Crit. Care Med. 1999; 160: 594–599.

21. Rodrigo G.J., Castro-Rodriguez J.A. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 2005; 60:740–746.

22. Lemanske R.F. Jr., Sorkness C.A., Mauger E.A. et al.Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. J.A.M.A. 2001; 285: 2594–2603.

23. Laviolette M., Malmstrom K., Lu S. et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast / Beclomethasone Additivity Group. Am. J. Respir. Crit. Care Med. 1999; 160: 1862–1868.

24. Vaquerizo M.J., Casan P., Castillo J. et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58: 204–210. [Published erratum appears in Thorax 2003; 58: 370.].

25. Price D.B., Hernandez D., Magyar P. et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211–216.

26. Lalloo U.G., Malolepszy J., Kozma D. et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; 123:1480–1487.

27. Reddel H.K., Jenkins C.R., Marks G.B. et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur. Respir. J. 2000; 16: 226–235. [Published erratum appears in Eur. Respir. J. 2000; 16: 579].

28. Pauwels R.A., Pedersen S., Busse W.W. et al. and Start Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361: 1071–1076.

29. Virchow J.C. Jr., Prasse A., Naya I. et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am. J. Respir. Crit. Care Med.2000; 162: 578–585.

30. D’Urzo A.D., Chapman K.R., Cartier A. et al. Effectiveness and safety of salmeterol in nonspecialist practice settings.Chest 2001; 119: 714–719.

31. Chan-Yeung M., Chang J.H., Manfreda J. et al. Changes in peak flow, symptom score, and the use of medications during acute exacerbations of asthma. Am. J. Respir. Crit. Care Med. 1996; 154: 889–893.

32. Canonica G.W., Castellani P., Cazzola M. et al. Adjustable maintenance dosing with budesonide / formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulm.Pharmacol. Ther. 2004; 17: 239–247.

33. Vogelmeier C., D’Urzo A., Pauwels R. et al. Budesonide /formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J. 2005; 26:819–828. [Published erratum appears in Eur. Respir. J.2005; 26: 1191].

34. O’Byrne P.M., Bisgaard H., Godard P.P. et al. Budesonide /formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med. 2005; 171: 129–136.

35. ten Brinke A., Sterk P.J., Masclee A.A.M. et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur. Respir. J. 2005; 26: 812–818.

36. Heinig J.H., Boulet L.P., Croonenborghs L., Mollers M.J. The effect of high-dose fluticasone propionate and budesonide on lung function and asthma exacerbations in patients with severe asthma. Respir. Med. 1999; 93: 613–620.

37. FitzGerald J.M., Becker A., Sears M.R. et al. Canadian Asthma Exacerbation Study Group. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550–556.

38. Harrison T.W., Oborne J., Newton S., Tattersfield A.E.Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomized controlled trial. Lancet 2004; 363: 271–275.

39. Levy M.L., Stevenson C., Maslen T. Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax 1996; 51: 1087–1092.

40. Sont J.K., Willems L.N., Bel E.H. et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term

41. treatment. The AMPUL Study Group. Am. J. Respir. Crit.Care Med. 1999; 159: 1043–1051.

42. Papi A., Canonica G.W., Maestrelli P. et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N. Engl. J. Med. 2007; 356: 2040–2052.

43. Lazarus S.C., Boushey H.A., Fahy J.V. et al. Longacting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. J.A.M.A. 2001; 285:2583–2593.

44. Lanier B.Q., Corren J., Lumry W. et al. Omalizumab is effective in the long-term control of severe allergic asthma.Ann. Allergy Asthma Immunol. 2003; 91: 154–159.

45. Pifferi M., Baldini G., Marrazzini G. et al. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy 2002; 57: 785–790.

46. Barnes N.C., Miller C.J. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. Thorax 2000; 55: 478–483.

47. Kavuru M., Melamed J., Gross G. et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, doubleblind, placebo-controlled trial. J. Allergy Clin. Immunol.2000; 105: 1108–1116.

48. Dennis S.M., Sharp S.J., Vickers M.R. et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000; 355: 1675–1679.

49. Pont L.G., van der Werf G.T., Denig P., Haaijer-Ruskamp F.M.Identifying general practice patients diagnosed with asthma and their exacerbation episodes from prescribing data.Eur. J. Clin. Pharmacol. 2002; 57: 819–825.

50. Adams R.J., Boath K., Homan S. et al. A randomized trial of peak-flow and symptom-based action plans in adults with moderate-to-severe asthma. Respirology 2001; 6: 297–304.

51. Côté J, Cartier A., Malo J.-L. et al. Compliance with peak expiratory flow monitoring in home management of asthma. Chest 1998; 113: 968–972.

52. Wensley D., Silverman M. Peak flow monitoring for guided selfmanagement in childhood asthma: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2004; 170:606–612.

53. Reddel H.K., Vincent S.D., Civitico J. The need for standardisation of peak flow charts. Thorax 2005; 60:164–167.

54. Bateman E.D., Boushey H.A., Bousquet J. et al. and Goal Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170: 836–844.

55. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 173: 842–846.

56. Aaron S.D., Fergusson D., Marks G.B. et al. Counting,analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008; 63: 122–128.

57. Matz J., Emmett A., Rickard K., Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J. Allergy Clin. Immunol. 2001; 107: 783–789.

58. Rabe K.F., Pizzichini E., Stallberg B. et al. Budesonide /formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129: 246–256.

59. Bisgaard H., Le Roux P., Bjamer D. et al. Budesonide / formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006; 130: 1733–1743.

60. Bel E.H. Clinical phenotypes of asthma. Curr. Opin. Pulm.Med. 2004; 10: 44–50.

61. Wenzel S.E. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368: 804–813.

62. Reddel H., Ware S., Marks G. et al. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353: 364–369. [Published erratum appears in Lancet 1999; 353: 758].

63. Jenkins C.R., Thien F.C.K., Wheatley J.R., Reddel H.K.Traditional and patientcentred outcomes with three classes of asthma medication. Eur. Respir. J. 2005; 26: 36–44.

64. Sullivan S.D., Wenzel S.E., Bresnahan B.W. et al. Association of control and risk of severe asthmarelated events in severe or difficulttotreat asthma patients. Allergy 2007;62: 655–660.

65. Jones S.L., Kittelson J., Cowan J.O. et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am. J. Respir. Crit. Care Med.2001; 164: 738–743.

66. Pijnenburg M.W.H., Bakker E.M., Lever S. et al.High fractional concentration of nitric oxide in exhaled air despite steroid treatment in asthmatic children. Clin. Exp. Allergy 2005; 35: 920–925.

67. Gelb A.F., Flynn Taylor C., Shinar C.M. et al. Role of spirometry and exhaled nitric oxide to predict exacerba tions in treated asthmatics. Chest 2006; 129: 1492–1499.

68. Osborne M.L., Pedula K.L., O’Hollaren M. et al. Assessing future need for acute care in adult asthmatics: the profile of asthma risk study: a prospective health maintenance organization-based study. Chest 2007; 132: 1151–1161.

69. Bailey W.C., Higgins D.M., Richards B.M., Richards J.M.Asthma severity: a factor analytic investigation. Am. J.Med. 1992; 93: 263–269.

70. Kerstjens H.A.M., Brand P.L.P., Jong P.M.D. et al. for the Dutch CNSLD Study Group. Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. Thorax 1994; 49: 1109–1115.

71. Reddel H.K., Salome C.M., Peat J.K., Woolcock A.J. Which index of peak expiratory flow is most useful in the management of stable asthma? Am. J. Respir. Crit. Care Med.1995; 151: 1320–1325.

72. Green R.H., Brightling C.E., Woltmann G. et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57:875–879.

73. Jones P.W. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur.Respir. J. 2002; 19: 398–404.

74. Diette G.B., Patino C.M., Merriman B. et al. Patient factors that physicians use to assign asthma treatment. Arch.Intern. Med. 2007; 167: 1360–1366.

75. Rubinfield A.R., Pain M.C.F. The perception of asthma.Lancet 1976; 1: 882–884.

76. Leckie M.J. Antiinterleukin5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am. J.Respir. Med. 2003; 2: 245–259.

77. Gibson P.G., Wong B.J.O., Hepperle M.J.E. et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin. Exp.Allergy. 1992; 22: 525–532.

78. Combescure C., Chanez P., Saint*Pierre P. et al. Association pour la Recherche en Intelligence Artificielle group. Assessment of variations in control of asthma over time. Eur. Respir. J. 2003; 22: 298–304.

79. Bateman E.D., Bousquet J., Busse W.W. et al. Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy 2008; 63: 932–938.

80. Gibson P.G., Powell H., Ducharme F.M. Differential effects of maintenance longacting betaagonist and inhaled corticosteroid on asthma control and asthma exacerbations.J. Allergy Clin. Immunol. 2007; 119: 344–350.

81. Reznik M., Sharif I., Ozuah P.O. Classifying asthma severity: prospective symptom diary or retrospective symptom recall? J. Adolesc. Hlth 2005; 36: 537–538.

82. Simmons M.S., Nides M.A., Rand C.S. et al. Trends in compliance with bronchodilator use between follow-up visits in a clinical trial. Chest 1996; 109: 963–968.

83. Juniper E.F., O’Byrne P.M., Ferrie P.J. et al. Measuring asthma control. clinic questionnaire or daily diary? Am. J.Respir. Crit. Care Med. 2000; 162: 1330–1334.

84. Reddel H.K., Toelle B.G., Marks G.B. et al. Analysis of adherence to peak flow monitoring when recording of data is electronic. Br. Med. J. 2002; 324: 146–147.

85. Santanello N.C., Barber B.L., Reiss T.F. et al. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur. Respir. J. 1997; 10: 646–651.

86. Santanello N.C., Demuro-Mercon C., Davies G. et al.Validation of a pediatric asthma caregiver diary. J. Allergy Clin. Immunol. 2000; 106:861–866.

87. Santanello N.C., Davies G., Galant S.P. et al. Validation of an asthma symptom diary for interventional studies. Arch.Dis. Child. 1999; 80: 414–420.

88. Koop A., Mosges R. The use of handheld computers in clinical trials. Control. Clin. Trials. 2002; 23: 469–480.

89. Reddel H.K. Electronic monitoring of lung function in asthma: technical aspects, clinical applications. In: Gibson P.G., ed. Monitoring asthma. Boca Raton, FL: Taylor and Francis; 2005.

90. Reddel H.K., Ware S.I., Salome C.M. et al. Pitfalls in processing home electronic spirometric data in asthma. Eur.Respir. J.1998; 12: 853–858.

91. Palmblad M., Tiplady B. Electronic diaries and questionnaires: designing user interfaces that are easy for all patients to use. Qual. Life Res. 2004; 13: 1199–1207.

92. Goldsmith C.H. The effect of compliance distributions on therapeutic trials. In: Haynes R.B., Taylor D.W., Sackett D.L., eds. Compliance in health care. Baltimore, MD: Johns Hopkins University Press; 1979. 297–308.

93. Gwaltney C.J., Shields A.L., Shiffman S. Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: a meta-analytic review. Value Hlth 2008; 11: 322–333.

94. Fuhlbrigge A.L., Adams R.J., Guilbert T.W. et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am. J. Respir. Crit. Care Med. 2002; 166: 1044–1049.

95. Magzamen S., Mortimer K.M., Davis A., Tager I.B. School-based asthma surveillance: a comparison of student and parental report. Pediatr. Allergy Immunol. 2005; 16:669–678.

96. Horak E., Grassl G., Skladal D., Ulmer H. Lung function and symptom perception in children with asthma and their parents. Pediatr. Pulmonol. 2003; 35: 23–28.

97. Dales R.E., White J., Bhumgara C., McMullen E. Parental reporting of childrens’ coughing is biased. Eur. J. Epidemiol. 1997; 13: 541–545.

98. Levy M.L., Godfrey S., Irving C.S. et al. Wheeze detection: recordings vs assessment of physician and parent. J. Asthma 2004; 41: 845–853.

99. Michel G., Silverman M., Strippoli M.P.F. et al. Parental understanding of wheeze and its impact on asthma prevalence estimates. Eur. Respir. J. 2006; 28: 1124–1130.

100. Pao C.S., McKenzie S.A. Randomized controlled trial of fluticasone in preschool children with intermittent wheeze.Am. J. Respir. Crit. Care Med. 2002; 166: 945–949.

101. Stahl E. Correlation between objective measures of airway calibre and clinical symptoms in asthma: a systematic review of clinical studies. Respir. Med. 2000; 94: 735–741.

102. Tasche M.J., van der Wouden J.C., Uijen J.H. et al. Randomised placebocontrolled trial of inhaled sodium cromoglycate in 1–4-year-old children with moderate asthma.Lancet 1997; 350: 1060–1064. [Published erratum appears in Lancet 1998; 351: 376].

103. Sheikh A., Hurwitz B., Sibbald B. et al. House dust mite barrier bedding for childhood asthma: randomised placebo controlled trial in primary care. B.M.C. Fam. Pract. 2002;3: 12.

104. Slader C.A., Reddel H.K., Spencer L.M. et al. Double-blind randomised controlled trial of two different breathing techniques in the management of asthma. Thorax 2006;61: 651–656.

105. American Lung Association Asthma Clinical Research Centers; Peters S.P., Anthonisen N., Castro M. et al.Randomized comparison of strategies for reducing treatment in mild persistent asthma. N. Engl. J. Med. 2007;356: 2027–2039. [Published erratum appears in N. Engl. J.Med. 2007; 357: 728].

106. Lundborg M., Wille S., Bjermer L. et al. Maintenance plus reliever budesonide / formoterol compared with a higher maintenance dose of budesonide / formoterol plus formoterol as reliever in asthma: an efficacy and cost-effec-tiveness study. Curr. Med. Res. Opin. 2006; 22: 809–821.

107. Eggleston P.A., Malveaux F.J., Butz A.M. et al. Medications used by children with asthma living in the inner city.Pediatrics 1998; 101: 349–354.

108. Ferguson A.E., Gibson N.A., Aitchison T.C., Paton J.Y.Measured bronchodilator use in preschool children with asthma. Br. Med. J. 1995; 310: 1161–1164.

109. Kim K.T., Ginchansky E.J., Friedman B.F. et al. Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy. Ann.Allergy Asthma Immunol. 2000; 85: 398–406.

110. Zetterstrom O., Buhl R., Mellem H. et al. Improved asthma control with budesonide / formoterol in a single inhaler,compared with budesonide alone. Eur. Respir. J. 2001; 18:262–268.

111. Szefler S.J., Boushey H.A., Pearlman D.S. et al. Time to onset of effect of fluticasone propionate in patients with asthma. J. Allergy Clin. Immunol. 1999; 103: 780–788.

112. Santanello N.C., Zhang J., Seidenberg B. et al. What are minimal important changes for asthma measures in a clinical trial? Eur. Respir. J. 1999; 14: 23–27.

113. Juniper E.F., Svensson K., Mork A.C., Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir. Med.2005; 99: 553–558.

114. Enright P.L., Sherrill D.L., Lebowitz M.D. Ambulatory monitoring of peak expiratory flow: reproducibility and quality control. Chest 1995; 107: 657–661.

115. Chan D.S., Callahan C.W., Sheets S.J. et al. An Internet-based store-and-forward video home telehealth system for improving asthma outcomes in children. Am. J. Hlth Syst.Pharm. 2003; 60: 1976–1981.

116. Boezen H.M., Schouten J.P., Postma D.S., Rijcken B. Distribution of peak expiratory flow variability by age, gender and smoking habits in a random population sample aged 20–70 years. Eur. Respir. J. 1994; 7: 1814–1820.

117. Brouwer A.F., Roorda R.J., Brand P.L. Home spirometry and asthma severity in children. Eur. Respir. J. 2006; 28: 1131–1137.

118. Miller M.R., Crapo R., Hankinson J. et al. General considerations for lung function testing. Eur. Respir. J. 2005; 26:153–161.

119. Gannon P.F.G., Newton D.T., Pantin C.F.A., Burge P.S. Effect of the number of peak expiratory flow readings perday on the estimation of diurnal variation. Thorax 1998;53: 790–792.

120. Reddel H.K., Ware S.I., Salome C.M. et al. Standardization of ambulatory peak flow monitoring: the importance of recent beta2-agonist inhalation. Eur. Respir. J. 1998; 12:309–314.

121. Ahrens R.C., Teresi M.E., Han S.H. et al. Asthma stability after oral prednisone: a clinical model for comparing inhaled steroid potency. Am. J. Respir. Crit. Care Med.2001; 164: 1138–1145.

122. Busse W., Raphael G.D., Galant S. et al.; Fluticasone Proprionate Clinical Research Study Group. Low-dose fluticasone propionate compared with montelukast for firstline treatment of persistent asthma: a randomized clinical trial. J. Allergy Clin. Immunol. 2001; 107:461–468.

123. Reddel H.K., Belousova E.G., Marks G.B., Jenkins C.R. Does continuous use of inhaled corticosteroids improve outcomes in mild asthma? A doubleblind randomized controlled trial. Prim. Care Respir. J. 2008; 17: 39–45.

124. Reddel H.K., Marks G.B., Jenkins C.R. When can personal best peak flow be determined for asthma action plans?Thorax 2004; 59: 922–924.

125. Brand P.L.P., Duiverman E.J., Waalkens H.J. et al.; Dutch CNSLD Study Group. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction,and hyperresponsiveness during long term treatment with inhaled corticosteroids. Thorax 1999; 54: 103–107.

126. Noonan M.J., Chervinsky P., Brandon M. et al.; Montelukast Asthma Study Group. Montelukast, a potent leukotriene receptor antagonist, causes doserelated improvements in chronic asthma. Eur. Respir. J. 1998; 11: 1232–1239.

127. Tamaoki J., Kondo M., Sakai N. et al.; Tokyo Joshi-Idai Asthma Research Group. Effect of suplatast tosilate, a Th2cytokine inhibitor, on steroiddependent asthma: a double-blind randomised study. Lancet 2000; 356: 273–278.

128. Boulet L.P., Cowie R.L., Negro R.D. et al. Comparison of once-with twicedaily dosing of fluticasone propionate in mild and moderate asthma. Can. Respir. J. 2000; 7:239–247.

129. Siersted H.C., Hansen H.S., Hansen N.-C.G. et al. Evaluation of peak expiratory flow variability in an adolescent population sample. The Odense Schoolchild Study. Am. J. Respir. Crit. Care Med. 1994; 149: 598–603.

130. Hetzel M.R., Clark T.J.H. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate.Thorax 1980; 35: 732–738.

131. Gibson P.G., Wlodarczyk J., Hensley M.J. Using quality-control analysis of peak expiratory flow recordings to guide therapy for asthma. Ann. Intern. Med. 1995; 123: 488–492.

132. Levy M.L., Robb M., Allen J. et al. A randomized controlled evaluation of specialist nurse education following accident and emergency department attendance for acute asthma. Respir. Med. 2000; 94: 900–908.

133. Frey U., Brodbeck T., Majumdar A. et al. Risk of severe asthma episodes predicted from fluctuation analysis of airway function. Nature 2005; 438: 667–670.

134. Boushey H.A., Sorkness C.A., King T.S. et al. Daily versus as-needed corticosteroids for mild persistent asthma.N. Engl. J. Med. 2005; 352: 1519–1528.

135. Arets H.G., Kamps A.W., Brackel H.J. et al. Children with mild asthma: do they benefit from inhaled corticosteroids?Eur. Respir. J. 2002; 20: 1470–1475.

136. Lambert P.C., Burton P.R., Abrams K.R., Brooke A.M. The analysis of peak expiratory flow data using a three-level hierarchical model. Stat. Med. 2004; 23: 3821–3839.

137. Dorinsky P.M., Edwards L.D., Yancey S.W., Rickard K.A.Use of changes in symptoms to predict changes in lung function in assessing the response to asthma therapy. Clin.Ther. 2001; 23: 701–714.

138. Miller M.R., Hankinson J., Brusasco V. et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26: 319–338.

139. Enright P.L., Beck K.C., Sherrill D.L. Repeatability of spirometry in 18,000 adult patients. Am. J. Respir. Crit. Care Med. 2004; 169: 235–238.

140. Beydon N., Davis S.D., Lombardi E. et al. An official American Thoracic Society / European Respiratory Society statement: pulmonary function testing in preschool children. Am. J. Respir. Crit. Care Med. 2007; 175:1304–1345.

141. Cockcroft D.W., Jokic R., Marciniuk D.D., Fitzpatrick M.F.The current dilemma with spirometric inclusion criteria for asthma drug trials. Ann. Allergy Asthma Immunol.1997; 79: 226–228.

142. Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur. Respir. J. 2005; 26:948–968.

143. Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur. Respir. J. Suppl. 1993;16: 5–40.

144. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general US population. Am. J. Respir. Crit. Care Med. 1999; 159: 179–187.

145. Perez-Padilla R., Valdivia G., Muino A. et al. Spirometric reference values in 5 large Latin American cities for subjects aged 40 years or over. Arch. Bronconeumol. 2006; 42:317–325.

146. Coates A.L., Desmond K.J., Demizio D., Allen P.D. Sources of variation in FEV1. Am. J. Respir. Crit. Care Med. 1994;149: 439–443.

147. Enright P.L., Lebowitz M.D., Cockroft D.W. Physiologic measures: pulmonary function tests: asthma outcome. Am. J. Respir. Crit. Care Med. 1994; 149: S9–S18.

148. Kunzli N., Ackermann-Liebrich U., Keller R. et al. Variability of FVC and FEV1 due to technician, team, device and subject in an eight centre study: three quality control studies in SAPALDIA. Swiss Study on Air Pollution and Lung Disease in Adults. Eur. Respir. J. 1995; 8: 371–376.

149. Zeiger R.S., Dawson C., Weiss S. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP).J. Allergy Clin. Immunol. 1999; 103: 376–387.

150. Paull K., Covar R., Jain N. et al. Do NHLBI lung function criteria apply to children? A crosssectional evaluation of childhood asthma at National Jewish Medical and Research Center, 1999–2002. Pediatr. Pulmonol. 2005;39: 311–317.

151. Spahn J.D., Cherniack R., Paull K., Gelfand E.W. Is forced expiratory volume in one second the best measure of severity in childhood asthma? Am. J. Respir. Crit. Care Med.2004; 169: 784–786.

152. Barnes N., Wei L.X., Reiss T.F. et al. Analysis of montelukast in mild persistent asthmatic patients with nearnormal lung function. Respir. Med. 2001; 95: 379–386.

153. Huhti E., Poukkula A. Clinical comparison of fenoterol and albuterol administered by inhalation: a double-blind study. Chest 1978; 73: 348–351.

154. Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47–55.

155. Zeiger R.S., Szefler S.J., Phillips B.R. et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J. Allergy Clin. Immunol.2006; 117: 45–52.

156. van Rensen E.L.J., Sont J.K., Evertse C.E. et al. AMPUL Study Group. Bronchial CD8 cell infiltrate and lung function decline in asthma. Am. J. Respir. Crit. Care Med.2005; 172: 837–841.

157. Tantisira K.G., Fuhlbrigge A.L., Tonascia J. et al.; Childhood Asthma Management Program Research Group. Bronchodilation and bronchoconstriction: predictors of future lung function in childhood asthma. J. Allergy Clin.Immunol. 2006; 117: 1264–1271.

158. Szefler S.J., Martin R.J., King T.S. et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy Clin. Immunol. 2002; 109: 410–418.

159. Schatz M., Mosen D., Apter A.J. et al. Relationships among quality of life, severity, and controlmeasures in asthma: an evaluation using factor analysis. J. Allergy Clin. Immunol. 2005; 115: 1049–1055.

160. Juniper E.F., O’Byrne P.M., Guyatt G.H. et al. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 1999; 14: 902–907

161. Shingo S., Zhang J., Reiss T.F. Correlation of airway obstruction and patientreported endpoints in clinical studies. Eur. Respir. J. 2001; 17: 220–224.

162. Zhang J., Yu C., Holgate S.T., Reiss T.F. Variability and lack of predictive ability of asthma endpoints in clinical trials. Eur. Respir. J. 2002; 20: 1102–1109.

163. Sharek P.J., Mayer M.L., Loewy L. et al. Agreement among measures of asthma status: a prospective study of low-income children with moderate to severe asthma.Pediatrics 2002; 110: 797–804.

164. Moy M.L., Israel E., Weiss S.T. et al. Asthma Clinical Research Network. Clinical predictors of health-related quality of life depend on asthma severity. Am. J. Respir.Crit. Care Med. 2001; 163: 924–929.

165. Juniper E.F., O’Byrne P.M., Roberts J.N. Measuring asthma control in group studies: do we need airway calibre and rescue beta2-agonist use? Respir. Med.2001; 95: 319–323.

166. Lim S., Jatakanon A., John M. et al. Effect of inhaled budesonide on lung function and airway inflammation:assessment by various inflammatory markers in mild asthma. Am. J. Respir. Crit. Care Med. 1999; 159: 22–30.

167. Covar R.A., Spahn J.D., Murphy J.R., Szefler S.J.;Childhood Asthma Management Program ResearchGroup. Progression of asthma measured by lung function in the childhood asthma management program. Am. J. Respir. Crit. Care Med. 2004; 170: 234–241.

168. Aburuz S., McElnay J., Gamble J. et al. Relationship between lung function and asthma symptoms in patients with difficult to control asthma. J. Asthma 2005; 42:859–864.

169. Booth H., Richmond I., Ward C. et al. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 1995; 152: 45–52.

170. Ulrik C.S., Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest 1995; 108: 10–15.

171. Fuhlbrigge A.L., Weiss S.T., Kuntz K.M., Paltiel A.D.;CAMP Research Group. Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. Pediatrics 2006; 118:e347–e355.

172. Li D., German D., Lulla S. et al. Prospective study of hospitalization for asthma: a preliminary risk factor model.Am. J. Respir. Crit. Care Med. 1995; 151: 647–655.

173. Fuhlbrigge A.L., Kitch B.T., Paltiel A.D. et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. J. Allergy Clin. Immunol. 2001; 107: 61–67.

174. Kitch B.T., Paltiel A.D., Kuntz K.M. et al. A single measure of FEV1 is associated with risk of asthma attacks in longterm follow-up. Chest 2004; 126: 1875–1882.

175. Fuhlbrigge A.L. Asthma severity and asthma control:symptoms, pulmonary function, and inflammatory markers. Curr. Opin. Pulm. Med. 2004; 10: 1–6.

176. Thiadens H.A., De Bock G.H., Van Houwelingen J.C. et al.Can peak expiratory flow measurements reliably identify the presence of airway obstruction and bronchodilator response as assessed by FEV1 in primary care patients presenting with a persistent cough? Thorax 1999; 54: 1055–1060.

177. Covar R.A., Szefler S.J., Martin R.J. et al. Relations between exhaled nitric oxide and measures of disease activity among children with mild-tomoderate asthma. J. Pediatr.2003; 142: 469–475.

178. Grazzini M., Scano G., Foglio K. et al. Relevance of dysp-noea and respiratory function measurements in monitoring of asthma: a factor analysis. Respir. Med. 2001; 95:246–250.

179. Assefa D., Amin N., Dozor A.J. Effect of deep inspiration on airway caliber in children with asthma. Pediatr. Pulmonol.2004; 38: 406–412.

180. Hellinckx J., De Boeck K., Bande-Knops J. et al. Bronchodilator response in 3–6.5 years old healthy and stable asthmatic children. Eur. Respir. J. 1998; 12: 438–443.

181. Kanengiser S., Dozor A.J. Forced expiratory maneuvers in children aged 3 to 5 years. Pediatr. Pulmonol. 1994; 18:144–149.

182. Oostveen E., MacLeod D., Lorino H. et al.; ERS Task Force on Respiratory Impedence Measurements. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur. Respir. J. 2003; 22: 1026–1041.

183. Timonen K.L., Randell J.T., Salonen R.O., Pekkanen J.Short-term variations in oscillatory and spirometric lung function indices among school children. Eur. Respir. J. 1997; 10: 82–87.

184. Sterk P.J., Fabbri L.M., Quanjer P.H. et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur.Respir. J. Suppl. 1993; 16: 53–83.

185. Joos G.F., O’Connor B., Anderson S.D. et al. Indirect airway challenges. Eur. Respir. J.2003; 21:1050–1068.

186. Crapo R.O., Casaburi R., Coates A.L. et al. Guidelines for methacholine and exercise challenge testing-1999. Am. J.Respir. Crit. Care Med. 2000; 161: 309–329.

187. Koskela H.O., Hyvarinen L., Brannan J.D. et al. Responsiveness to three bronchial provocation tests in patients with asthma. Chest 2003; 124: 2171–2177.

188. Cockcroft D.W., Davis B.E. The bronchoprotective effect of inhaling methacholine by using total lung capacity inspirations has a marked influence on the interpretation of the test result. J. Allergy Clin. Immunol. 2006; 117:1244–1248.

189. O’Connor G., Sparrow D., Taylor D. et al. Analysis of dose–response curves to methacholine: an approach suitable for population studies. Am. Rev. Respir. Dis. 1987;136: 1412–1417.

190. Delacourt C., Lorino H., Fuhrman C. et al. Comparison of the forced oscillation technique and the interrupter technique for assessing airway obstruction and its reversibility in children. Am. J. Respir. Crit. Care Med. 2001; 164:965–972.

191. Malmberg L.P., Nikander K., Pelkonen A.S. et al. Acceptability, reproducibility, and sensitivity of forced expiratory volumes and peak expiratory flow during bronchial challenge testing in asthmatic children. Chest 2001; 120:1843–1849.

192. Hargreave F.E., Ryan G., Thomson N.C. et al. Bronchial responsiveness to histamine or methacholine in asthma:measurement and clinical significance. J. Allergy Clin.Immunol. 1981; 68: 347–355.

193. Peat J.K., Salome C.M., Bauman A. et al. Repeatability of histamine bronchial challenge and comparability with methacholine bronchial challenge in a population of Australian schoolchildren. Am. Rev. Respir. Dis. 1991;144: 338–343.

194. Jayet P.-Y., Schindler C., Kunzli N. et al. Reference values for methacholine reactivity (SAPALDIA study). Respir. Res. 2005; 6: 131.

195. Fowler S.J., Dempsey O.J., Sims E.J., Lipworth B.J.Screening for bronchial hyperresponsiveness using methacholine and adenosine monophosphate: relationship to asthma severity and beta(2)-receptor genotype. Am. J.Respir. Crit. Care Med. 2000; 162: 1318–1322.

196. De Meer G., Heederik D.J., Brunekreef B., Postma D.S.Repeatability of bronchial hyperresponsiveness to adenosine-59-monophosphate (AMP) by a short dosimeter protocol. Thorax 2001; 56: 362–365.

197. Chinn S., Burney P.G., Britton J.R. et al. Comparison of PD20 with two alternative measures of response to histamine challenge in epidemiological studies. Eur. Respir.J.1993; 6: 670–679.

198. Inman M.D.,Hamilton A.L., Kerstjens H.A. et al. The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs. J. Allergy Clin. Immunol.1998; 101: 342–348.

199. Bel E.H., Zwinderman A.H., Timmers M.C. et al. The protective effect of a beta 2 agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Thorax 1991;46: 9–14.

200. Rabe K.F., Jorres R., Nowak D. et al. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am.Rev. Respir. Dis. 1993; 147: 1436–1441.

201. van Grunsven P.M., van Schayck C.P., Molema J. et al.Effect of inhaled corticosteroids on bronchial responsiveness in patients with ‘‘corticosteroid naive’’ mild asthma: a metaanalysis. Thorax 1999; 54: 316–322.

202. Currie G.P., Fowler S.J., Lipworth B.J. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Ann. Allergy Asthma Immunol 2003; 90:194–198.

203. van Essen-Zandvliet E.E., Hughes M.D., Waalkens H.J. et al.Effects of 22 months of treatment with inhaled corticosteroids and / or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma.The Dutch Chronic Non-specific Lung Disease Study Group. Am. Rev. Respir. Dis. 1992; 146: 547–554.

204. Doull L.J., Sandall D., Smith S. et al. Differential inhibitory effect of regular inhaled corticosteroid on airway responsiveness to adenosine 59 monophosphate, metha-choline, and bradykinin in symptomatic children with recurrent wheeze. Pediatr. Pulmonol. 1997; 23: 404–411.

205. van den Berge M., Kerstjens H.A., Meijer R.J. et al.Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am. J. Respir. Crit. Care Med.2001; 164: 1127–1132.

206. Ward C., Reid D.W., Orsida B.E. et al. Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to metha-choline in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis. Clin. Exp. Allergy 2005; 35:1565–1571.

207. Boulet L.P., Turcotte H., Boutet M. et al. Influence of natural antigenic exposure on expiratory flows, methacholine responsiveness, and airway inflammation in mild allergic asthma. J. Allergy Clin. Immunol. 1993; 91: 883–893.

208. Xepapadaki P., Papadopoulos N.G., Bossios A. et al.Duration of postviral airway hyperresponsiveness in children with asthma: effect of atopy. J. Allergy Clin. Immunol. 2005; 116: 299–304.

209. Gilbert R., Auchincloss J.H. Jr. Post-test probability of asthma following methacholine challenge. Chest 1990; 97:562–565.

210. Berkman N., Avital A., Breuer R. et al. Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests. Thorax 2005; 60: 383–388.

211. O’Byrne P.M., Inman M.D. Airway hyperresponsiveness. Chest 2003; 123: 411S–416S.

212. Palmer L.J., Rye P.J., Gibson N.A. et al. Airway responsiveness in early infancy predicts asthma, lung function, and respiratory symptoms by school age. Am. J. Respir. Crit. Care Med. 2001; 163: 37–42.

213. Rasmussen F., Taylor D.R., Flannery E.M. et al. Risk factors for hospital admission for asthma from childhood to young adulthood: a longitudinal population study. J. Allergy Clin. Immunol. 2002; 110: 220–227.

214. Leuppi J.D., Salome C.M., Jenkins C.R. et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am. J. Respir. Crit.Care Med. 2001; 163: 406–412.

215. O’Connor G.T., Sparrow D., Weiss S.T. A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary function decline: the Normative Aging Study. Am. J. Respir. Crit. Care Med. 1995; 152: 87–92.

216. Grol M.H., Gerritsen J., Vonk J.M. et al. Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years: a 30year followup study. Am. J.Respir. Crit. Care Med. 1999; 160: 1830–1837.

217. Limb S.L., Brown K.C., Wood R.A. et al. Irreversible lung function deficits in young adults with a history of childhood asthma. J. Allergy Clin. Immunol. 2005; 116:1213–1219.

218. Brutsche M.H., Downs S.H., Schindler C. et al.; SAPALDIA Team. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006; 61: 671–677.

219. Szefler S.J., Phillips B.R., Martinez F.D. et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin.Immunol. 2005; 115: 233–242.

220. Nuijsink M., Hop W.C.J., Sterk P.J. et al. Longterm asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial. Eur. Respir. J.2007; 30: 457–466.

221. Sterk P.J. Heterogeneity of airway hyperresponsiveness: time for unconventional, but traditional, studies. J. Appl. Physiol. 2004; 96: 2017–2018.220. Cox G., Miller J.D., McWilliams A. et al. Bronchial thermoplasty for asthma. Am. J. Respir. Crit. Care Med. 2006;173: 965–969.

222. Bateman E.D., Bousquet J., Braunstein G.L. Is overall asthma control being achieved? A hypothesis-generating study.Eur. Respir. J. 2001; 17: 589–595.

223. Cockcroft D.W., Swystun V.A. Asthma control versus asthma severity. J. Allergy Clin. Immunol 1996; 98:1016–1018.

224. Boulet L.-P., Boulet V., Milot J. How should we quantify asthma control? A proposal. Chest 2002; 122: 2217–2223.

225. Ehrs P.-O., Nokela M., Stallberg B. et al. Brief questionnaires for patientreported outcomes in asthma: validation and usefulness in a primary care setting. Chest 2006; 129:925–932.

226. Nathan R.A., Sorkness C.A., Kosinski M. et al. Development of the asthma control test: a survey for assessing asthma control. J. Allergy Clin. Immunol. 2004; 113: 59–65.

227. Vollmer W.M., Markson L.E., O'Connor E. et al. Association of asthma control with health care utilization and quality of life. Am. J. Respir. Crit. Care Med. 1999; 160:1647–1652.

228. Bateman E.D., Frith L.F., Braunstein G.L. Achievinggui-deline-based asthma control: does the patient benefit? Eur.Respir. J. 2002; 20: 588–595.

229. Roche N., Morel H., Martel P., Godard P. Clinical practice guidelines: medical followup of patients with asthma –adults and adolescents. Respir. Med. 2005; 99: 793–815.

230. Joint Task Force on Practice Parameters, American Academy of Allergy Asthma and Immunology, American College of Allergy Asthma and Immunology, and Joint Council of Allergy Asthma and Immunology. Attaining optimal asthma control: a practice parameter. J. Allergy Clin. Immunol. 2005; 116: S3–S11. [Published erratum appears in J. Allergy Clin. Immunol. 2006; 117: 262].

231. Woodcock A.A., Bagdonas A., Boonsawat W. et al. Steering Committee and Investigators. Improvement in asthma endpoints when aiming for total control: salmeterol / fluticasone propionate versus fluticasone propionate alone. Prim. Care Respir. J. 2007; 16: 155–161.

232. Bateman E.D., Clark T.J.H., Frith L. et al. and Goal Investigators Group. Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the GOAL study. J. Asthma 2007; 44:667–673.

233. Ferreira-Gonzalez I., Busse J.W., Heels-Ansdell D. et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. Br. Med. J. 2007; 334: 786.

234. Juniper E.F., Bousquet J., Abetz L., Bateman E.D. and The Goal Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir. Med. 2006; 100: 616–621.

235. Buhl R., Creemers J.P.H.M., Vondra V. et al. Once-daily budesonide / formoterol in a single inhaler in adults with moderate persistent asthma. Respir. Med. 2003; 97:323–330.

236. Sorkness C.A., Lemanske R.F. Jr., Mauger D.T. et al. Longterm comparison of 3 controller regimens for mildmoderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J. Allergy Clin. Immunol. 2007; 119:64–72. [Published erratum appears in J. Allergy Clin. Immunol. 2007; 120: 285].

237. Guilbert T.W., Morgan W.J., Krawiec M. et al. The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education network. Control. Clin. Trials 2004; 25: 286–310.

238. Baumgartner R.A., Martinez G., Edelman J.M. et al.Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone.Eur. Respir. J. 2003; 21: 123–128.

239. Spencer S., Mayer B., Bendall K.L., Bateman E.D.Validation of a guidelinebased composite outcome assessment tool for asthma control. Respir. Res. 2007; 8: 26.

240. Holt S., Kljakovic M., Reid J. POMS Steering Committee.Asthma morbidity, control and treatment in New Zealand:results of the Patient Outcomes Management Survey(POMS), 2001. N. Z. Med. J. 2003; 116: U436.

241. Lenoir M., Williamson A., Stanford R.H., Stempel D.A.Assessment of asthma control in a general population of asthmatics. Curr. Med. Res. Opin. 2006; 22: 17–22.

242. Thomas M., Kay S., Pike J. et al. The Asthma Control Test(ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational crosssectional survey. Prim. Care Respir. J. 2009; 18: 41–49.

243. Wallenstein G.V., Carranza-Rosenzweig J., Kosinski M. et al.A psychometric comparison of three patient-based measures of asthma control. Curr. Med. Res. Opin. 2007; 23:369–377.

244. Schatz M., Sorkness C.A., Li J.T. et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J. Allergy Clin.Immunol. 2006; 117: 549–556.

245. Peters S.P., Jones C.A., Haselkorn T. et al. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Webbased survey. J. Allergy Clin.Immunol. 2007; 119: 1454–1461.

246. Kosinski M., Kite A., Yang M. et al. Comparability of the Asthma Control Test telephone interview administration format with self-administered mail-out mail-back format.Curr. Med. Res. Opin. 2009; 25: 717–727.

247. Liu A.H., Zeiger R., Sorkness C. et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J. Allergy Clin. Immunol. 2007; 119: 817–825.

248. Schatz M., Mosen D.M., Kosinski M. et al. Validity of the Asthma Control Test completed at home. Am. J. Manag. Care 2007; 13: 661–667.

249. Vollmer W.M., Markson L.E., O'Connor E. et al. Association of asthma control with health care utilization:a prospective evaluation. Am. J. Respir. Crit. Care Med.2002; 165: 195–199.

250. Burton W.N., Connerty C.M., Schultz A.B. et al. Bank One's worksitebased asthma disease management program.J. Occup. Environ. Med. 2001; 43: 75–82.

251. Patel P.H., Welsh C., Foggs M.B. Improved asthma outcomes using a coordinated care approach in a large medical group. Dis. Manag. 2004; 7: 102–111.

252. Skinner E.A., Diette G.B., Algatt-Bergstrom P.J. et al. The Asthma Therapy Assessment Questionnaire (ATAQ) for children and adolescents. Dis. Manag. 2004; 7: 305–313.

253. Peters D., Chen C., Markson L.E. et al. Using an asthma control questionnaire and administrative data to predict health-care utilization. Chest 2006; 129: 918–924.

254. LeBlanc A., Robichaud P., Lacasse Y., Boulet L.P. Quantification of asthma control: validation of the Asthma Control Scoring System. Allergy 2007; 62: 120–125.

255. Pavord I.D., Pizzichini M.M., Pizzichini E., Hargreave F.E. The use of induced sputum to investigate airway inflammation. Thorax 1997; 52: 498–501.

256. Pizzichini E., Pizzichini M.M., Efthimiadis A. et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am.J. Respir. Crit. Care Med. 1996; 154: 308–317.

257. Scichilone N., Deykin A., Pizzichini E. et al. Monitoring response to treatment in asthma management: food for thought. Clin. Exp. Allergy 2004; 34: 1168–1177.

258. American Thoracic Society; European Respiratory Society.ATS / ERS Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am. J. Respir. Crit. Care Med. 2005; 171: 912–930.

259. Horvath I., Hunt J., Barnes P.J. et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur. Respir. J. 2005; 26: 523–548.

260. Kharitonov S.A. Exhaled markers of inflammatory lung diseases: ready for routine monitoring? Swiss. Med. Wkly 2004; 134: 175–192.

261. Green R.H., Brightling C.E., McKenna S. et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715–1721.

262. Jayaram L., Pizzichini M.M., Cook R.J. et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur. Respir. J. 2006; 27: 483–494.

263. Smith A.D., Cowan J.O., Brassett K.P. et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N. Engl. J. Med. 2005; 352: 2163–2173.

264. Horn B.R., Robin E.D., Theodore J., Van Kessel A. Total eosinophil counts in the management of bronchial asthma.N. Engl. J. Med. 1975; 292: 1152–1155.

265. Djukanovic R., Sterk P.J., Fahy J.V., Hargreave F.E. Standardised methodology of sputum induction and processing. Eur. Respir. J. 2002; 20: 1s–52s.

266. Covar R.A., Spahn J.D., Martin R.J. et al. Safety and application of induced sputum analysis in childhood asthma.J. Allergy Clin. Immunol. 2004; 114: 575–582.

267. Kips J.C., Peleman R.A., Pauwels R.A. Methods of examining induced sputum: do differences matter? Eur. Respir. J.1998; 11: 529–533.

268. Belda J., Leigh R., Parameswaran K. et al. Induced sputum cell counts in healthy adults. Am. J. Respir. Crit. Care Med. 2000; 161: 475–478.

269. Spanevello A., Confalonieri M., Sulotto F. et al. Induced sputum cellularity: reference values and distribution in normal volunteers. Am. J. Respir. Crit. Care Med. 2000;162: 1172–1174.

270. Thomas R.A., Green R.H., Brightling C.E. et al. The influence of age on induced sputum differential cell counts in normal subjects. Chest 2004; 126: 1811–1814.

271. Woodruff P.G., Khashayar R., Lazarus S.C. et al. Relationship between airway inflammation, hyperresponsiveness,and obstruction in asthma. J. Allergy Clin. Immunol.2001; 108: 753–758.

272. Brightling C.E., Monterio W., Green R.H. et al. Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. Respir.Med. 2001; 95: 999–1002.

273. in't Veen J.C., de Gouw H.W., Smits H.H. et al. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur. Respir. J.1996; 9: 2441–2447.

274. Pavord I.D., Brightling C.E., Woltmann G., Wardlaw A.J.Non-eosinophilic corticosteroid unresponsive asthma.Lancet 1999; 353: 2213–2214.

275. Pizzichini M.M.M., Pizzichini E., Clelland L. et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am. J. Respir. Crit.Care Med. 1997; 155: 1501–1508.

276. Pin I., Freitag A.P., O'Byrne P.M. et al. Changes in the cellular profile of induced sputum after allergen-induced asthmatic responses. Am. Rev. Respir. Dis. 1992; 145:1265–1269.

277. Pizzichini M.M., Kidney J.C., Wong B.J. et al. Effect of salmeterol compared with beclomethasone on allergeninduced asthmatic and inflammatory responses. Eur.Respir. J. 1996; 9: 449–455.

278. Pizzichini M.M., Pizzichini E., Clelland L. et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur. Respir. J.1999; 13: 15–21.

279. Green R.H., Brightling C.E., McKenna S. et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur.Respir. J. 2006; 27: 1144–1151.

280. Jatakanon A., Kharitonov S., Lim S., Barnes P.J. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999;54: 108–114.

281. Gibson P.G., Saltos N., Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2001; 163:32–36.

282. Belda J., Margarit G., Martinez C. et al. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations. Eur. Respir. J. 2007; 30:1143–1149.

283. Deykin A., Lazarus S.C., Fahy J.V. et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J. Allergy Clin. Immunol.2005; 115: 720–727.

284. Gibson P.G., Fujimura M., Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax 2002; 57: 178–182.

285. Brightling C.E., Monteiro W., Ward R. et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomized con-trolled trial. Lancet 2000; 356: 1480–1485.

286. Brightling C.E., Ward R., Wardlaw A.J., Pavord I.D. Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. Eur. Respir. J. 2000; 15: 682–686.

287. Jatakanon A., Uasuf C., Maziak W. et al. Neutrophilic inflammation in severe persistent asthma. Am. J. Respir.Crit. Care Med. 1999; 160: 1532–1539.

288. Bacci E., Cianchetti S., Bartoli M. et al. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 2006; 129:565–572.

289. Haldar P., Pavord I.D., Shaw D.E. et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 2008; 178: 218–224.

290. Jatakanon A., Lim S., Barnes P.J. Changes in sputum eosinophils predict loss of asthma control. Am. J. Respir. Crit. Care Med. 2000; 161: 64–72.

291. Chlumsky J., Striz I., Terl M., Vondracek J. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J. Int. Med. Res. 2006; 34:129–139.

292. Keatings V.M., Collins P.D., Scott D.M., Barnes P.J.Differences in interleukin-8 and tumor necrosis factoralpha in induced sputum from patients with chronicobstructive pulmonary disease or asthma. Am. J. Respir.Crit. Care Med. 1996; 153: 530–534.

293. Ricciardolo F.L.M., Sterk P.J., Gaston B., Folkerts G. Nitric oxide in health and disease of the respiratory system.Physiol. Rev. 2004; 84: 731–765.

294. Taylor D.R., Pijnenburg M.W., Smith A.D., De Jongste J.C.Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006; 61: 817–827.

295. Berry M.A., Shaw D.E., Green R.H. et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin. Exp. Allergy 2005; 35: 1175–1179.

296. Silkoff P.E. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children1999. Am. J. Respir. Crit. Care Med.1999; 160: 2104–2117.

297. Kharitonov S., Alving K., Barnes P.J. Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur. Respir. J.1997; 10: 1683–1693.

298. Kharitonov S.A., Gonio F., Kelly C. et al. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur. Respir. J. 2003; 21:433–438.

299. Tsoukias N.M., George S.C. A two-compartment model of pulmonary nitric oxide exchange dynamics. J. Appl.Physiol. 1998; 85: 653–666.

300. Berry M., Hargadon B., Morgan A. et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur. Respir. J. 2005; 25:986–991.

301. Buchvald F., Baraldi E., Carraro S. et al. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. J. Allergy Clin. Immunol. 2005; 115: 1130–1136.

302. Olin A.-C., Bake B., Toren K. Fraction of exhaled nitric oxide at 50 mL / s: reference values for adult lifelong neversmokers. Chest 2007; 131: 1852–1856.

303. Olivieri M., Talamini G., Corradi M. et al. Reference values for exhaled nitric oxide (reveno) study. Respir. Res. 2006;7: 94.

304. Travers J., Marsh S., Aldington S. et al. Reference ranges for exhaled nitric oxide derived from a random community survey of adults. Am. J. Respir. Crit. Care Med. 2007;176: 238–242.

305. Dressel H., de la Motte D., Reichert J. et al. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir. Med. 2008; 102:962–969.

306. Gratziou C., Lignos M., Dassiou M., Roussos C. Influence of atopy on exhaled nitric oxide in patients with stable asthma and rhinitis. Eur. Respir. J. 1999; 14: 897–901.

307. Kharitonov S.A., Robbins R.A., Yates D. et al. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am. J. Respir. Crit. Care Med. 1995; 152: 609–612.

308. Yates D.H., Breen H., Thomas P.S. Passive smoke inhalation decreases exhaled nitric oxide in normal subjects. Am.J. Respir. Crit. Care Med. 2001; 164: 1043–1046.

309. Maniscalco M., Di Mauro V., Farinaro E. et al. Transient decrease of exhaled nitric oxide after acute exposure to passive smoke in healthy subjects. Arch. Environ. Hlth2002; 57: 437–440.

310. Olin A.C., Rosengren A., Thelle D.S. et al. Height, age, and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample. Chest 2006; 130:1319–1325.

311. Jilma B., Kastner J., Mensik C. et al. Sex differences in concentrations of exhaled nitric oxide and plasma nitrate.Life Sci. 1996; 58: 469–476.

312. Tsang K.W., Ip S.K., Leung R. et al. Exhaled nitric oxide: the effects of age, gender and body size. Lung 2001; 179:83–91.

313. Taylor D.R., Mandhane P., Greene J.M. et al. Factors affecting exhaled nitric oxide measurements: the effect of sex. Respir. Res. 2007; 8: 82.

314. Kharitonov S.A., Logan-Sinclair R.B., Busset C.M., Shine-bourne E.A. Peak expiratory nitric oxide differences in men and women: relation to the menstrual cycle. Br. Heart J.1994; 72: 243–245.

315. Smith A.D., Cowan J.O., Brassett K.P. et al. Exhaled nitric oxide: a predictor of steroid response. Am. J. Respir. Crit.Care Med. 2005; 172: 453–459.

316. Muller K.C., Jorres R.A., Magnussen H., Holz O. Comparison of exhaled nitric oxide analysers. Respir. Med. 2005;99: 631–637.

317. Borrill Z., Clough D., Truman N. et al. A comparison of exhaled nitric oxide measurements performed using three different analysers. Respir. Med. 2006; 100: 1392–1396.

318. Kharitonov S.A., O'Connor B.J., Evans D.J., Barnes P.J.Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide. Am. J. Respir. Crit.Care Med. 1995; 151: 1894–1899.

319. Massaro A.F., Gaston B., Kita D. et al. Expired nitric oxide levels during treatment of acute asthma. Am. J. Respir.Crit. Care Med. 1995; 152: 800–803.

320. Kharitonov S.A., Yates D., Robbins R.A. et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994; 343: 133–135.

321. Jones S.L., Herbison P., Cowan J.O. et al. Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid:dose-response relationship. Eur. Respir. J. 2002; 20:601–608.

322. Kharitonov S.A., Donnelly L.E., Montuschi P. et al. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax 2002; 57: 889–896.

323. Pijnenburg M.W., Hofhuis W., Hop W.C., De Jongste J.C. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005; 60: 215–218.

324. Zacharasiewicz A., Wilson N., Lex C. et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am. J. Respir. Crit. Care Med. 2005; 171: 1077–1082.

325. Michils A., Baldassarre S., Van Muylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur. Respir. J. 2008; 31: 539–546.

326. Pijnenburg M.W., Bakker E.M., Hop W.C., De Jongste J.C.Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am. J. Respir. Crit.Care Med. 2005; 172: 831–836.

327. Shaw D.E., Berry M.A., Thomas M. et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am. J. Respir. Crit. Care Med.2007; 176: 231–237.

328. de Jongste J.C., Carraro S., Hop W.C. et al. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am. J. Respir. Crit. Care Med.2009; 179:93–97.

329. Szefler S.J., Mitchell H., Sorkness C.A. et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008;372: 1065–1072.

330. Montuschi P., Corradi M., Ciabattoni G. et al. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am. J. Respir. Crit. Care Med.1999; 160: 216–220.

331. Carraro S., Rezzi S., Reniero F. et al. Metabolomics applied to exhaled breath condensate in childhood asthma. Am. J. Respir. Crit. Care Med. 2007; 175: 986–990.

332. Venge P., Bystrom J., Carlson M. et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin. Exp. Allergy 1999; 29: 1172–1186.

333. Wolthers O.D., Heuck C. Circadian variations in serum eosinophil cationic protein, and serum and urine eosinophil protein X. Pediatr. Allergy Immunol. 2003; 14: 130–133.

334. Noguchi E., Iwama A., Takeda K. et al. The promoter polymorphism in the eosinophil cationic protein gene and its influence on the serum eosinophil cationic protein level.Am. J. Respir. Crit. Care Med. 2003; 167: 180–184.

335. Marks G.B., Kjellerby J., Luczynska C.M., Burney P.G. Serum eosinophil cationic protein: distribution and reproducibility in a randomly selected sample of men living in rural Norfolk, UK. Clin. Exp. Allergy 1998; 28:1345–1350.

336. Bjornsson E., Janson C., Hakansson L. et al. Serum eosinophil cationic protein in relation to bronchial asthma in a young Swedish population. Allergy 1994; 49: 730–736.

337. Pizzichini E., Pizzichini M.M., Efthimiadis A. et al. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. J. Allergy Clin. Immunol. 1997; 99:539–544.

338. Kips J.C., Pauwels R.A. Serum eosinophil cationic protein in asthma: what does it mean? Clin. Exp. Allergy 1998; 28:1–3.

339. Currie G.P., Syme-Grant N.J., McFarlane L.C. et al.Effects of low dose fluticasone / salmeterol combination on surrogate inflammatory markers in moderate persistent asthma. Allergy 2003; 58: 602–607.

340. Aldridge R.E., Hancox R.J., Cowant J.O. et al. Eosinophils and eosinophilic cationic protein in induced sputum and blood: effects of budesonide and terbutaline treatment.Ann. Allergy Asthma Immunol. 2002; 89: 492–497.

341. Visser M.J., Postma D.S., Brand P.L. et al. Influence of different dosage schedules of inhaled fluticasone propionate on peripheral blood cytokine concentrations in childhood asthma. Clin. Exp. Allergy 2002; 32: 1497–1503.

342. Meijer R.J., Postma D.S., Kauffman H.F. et al. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin. Exp. Allergy 2002;32: 1096–1103.

343. Lowhagen O., Wever A.M., Lusuardi M. et al. The inflammatory marker serum eosinophil cationic protein (ECP)compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients. Respir. Med. 2002; 96:95–101.

344. Dickinson J., Hutton S., Atkin A., Jones K. Reducing asthma morbidity in the community: the effect of a targeted nurse-run asthma clinic in an English general practice.Respir. Med.1997; 91: 634–640.

345. Balkrishnan R., Nelsen L.M., Kulkarni A.S. et al. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis. J. Asthma 2005; 42: 35–40.

346. Price D., Zhang Q., Kocevar V.S. et al. Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin. Exp. Allergy 2005; 35:282–287.

347. Senthilselvan A., Lawson J.A., Rennie D.C., Dosman J.A.Regular use of corticosteroids and low use of short-acting beta2-agonists can reduce asthma hospitalization. Chest 2005; 127: 1242–1251.

348. Sheth K., Borker R., Emmett A. et al. Costeffectiveness comparison of salmeterol / fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics 2002; 20: 909–918.

349. Hawkins G., McMahon A.D., Twaddle S. et al. Stepping down inhaled corticosteroids in asthma: randomized controlled trial. Br. Med. J. 2003; 326: 1115.

350. Kamps A.W., Roorda R.J., Kimpen J.L. et al. Impact of nurse-led outpatient management of children with asthma on healthcare resource utilisation and costs. Eur. Respir. J.2004; 23: 304–309.

351. Morice A.H., Wrench C. The role of the asthma nurse in treatment compliance and self-management following hospital admission. Respir. Med. 2001; 95: 851–856.

352. Mortimer K.M., Redline S., Kattan M. et al. Are peak flow and symptom measures good predictors of asthma hospitalizations and unscheduled visits? Pediatr. Pulmonol. 2001; 31: 190–197.

353. Schatz M., Zeiger R.S., Mosen D. et al. Improved asthma outcomes from allergy specialist care: a population-based crosssectional analysis. J. Allergy Clin. Immunol. 2005; 116: 1307–1313.

354. Turner M.O., Taylor D., Bennett R., Fitzgerald J.M. A randomized trial comparing peak expiratory flow and symptom self-management plans for patients with asthma attending a primary care clinic. Am. J. Respir. Crit. Care Med. 1998; 157: 540–546.

355. Heard A.R., Richards I.J., Alpers J.H. et al. Randomised controlled trial of general practice based asthma clinics. Med. J. Aust. 1999; 171: 68–71.

356. Schatz M., Rodriguez E., Falkoff R., Zeiger R.S. The relationship of frequency of followup visits to asthma outcomes in patients with moderate persistent asthma.J. Asthma 2003; 40: 49–53.

357. Schermer T.R., Thoonen B.P., van den Bloom G. et al.Randomized controlled economic evaluation of asthma self-management in primary health care. Am. J. Respir. Crit. Care Med. 2002; 166: 1062–1072.

358. Warman K.L., Silver E.J., Stein R.E. Asthma symptoms,morbidity, and antiinflammatory use in inner-city children. Pediatrics 2001; 108: 277–282.

359. Sturdy P.M., Butland B.K., Anderson H.R. et al. Deaths certified as asthma and use of medical services: a national case-control study. Thorax 2005; 60: 909–915.

360. Sullivan S.D., Buxton M., Andersson L.F. et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J. Allergy Clin. Immunol. 2003;112: 1229–1236.

361. Gruffydd-Jones K., Hollinghurst S., Ward S., Taylor G.Targeted routine asthma care in general practice using telephone triage. Br. J. Gen. Pract. 2005; 55: 918–923.

362. McCowan C., Neville R.G., Ricketts I.W. et al. Lessons from a randomized controlled trial designed to evaluate computer decision support software to improve the management of asthma. Med. Inform. Internet. Med. 2001;26: 191–201.

363. Simons F.E., Villa J.R., Lee B.W. et al. Montelukast added to budesonide in children with persistent asthma: a randomized, doubleblind, crossover study. J. Pediatr. 2001;138: 694–698.

364. Lee T.A., Fuhlbrigge A.L., Sullivan S.D. et al. Agreement between caregiver reported healthcare utilization and administrative data for children with asthma. J. Asthma 2007; 44: 189–194.

365. Holgate S.T., Chuchalin A.G., Hebert J. et al. Efficacy and safety of a recombinant antiimmunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy.2004; 34: 632–638.

366. Kemp J.P., Korenblat P.E., Scherger J.E., Minkwitz M.Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial(ACCEPT) in patients with asthma. J. Fam. Pract. 1999;48: 425–432.

367. Nathan RA, Bleecker ER, Kalberg C. A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. Am. J.Med. 2001; 111: 195–202.

368. Leflein J.G., Szefler S.J., Murphy K.R. et al. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial. Pediatrics 2002; 109: 866–872.

369. Bisgaard H., Price M.J., Maden C., Olsen N.A. Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children. Chest 2001;120: 1835–1842.

370. Corren J., Casale T., Deniz Y., Ashby M. Omalizumab,a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J. Allergy Clin. Immunol.2003; 111: 87–90.

371. Wilson S.R., Yamada E.G., Sudhakar R. et al. A controlled trial of an environmental tobacco smoke reduction intervention in lowincome children with asthma. Chest 2001;120: 1709–1722.

372. Humbert M., Beasley R., Ayres J. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.Allergy 2005; 60: 309–316.

373. Krishnan J.A., Riekert K.A., McCoy J.V. et al. Corticosteroid use after hospital discharge among high-risk adults with asthma. Am. J. Respir. Crit. Care Med. 2004; 170:1281–1285.

374. Rosenthal R.R., Busse W.W., Kemp J.P. et al. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Chest 1999;116: 595–602.

375. Pauwels R.A., Sears M.R., Campbell M. et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur. Respir. J. 2003; 22: 787–794.

376. Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353–365.

377. Chen H., Blanc P.D., Hayden M.L. et al. TENOR Study Group. Assessing productivity loss and activity impairment in severe or difficulttotreat asthma. Value Hlth2008; 11: 231–239.

378. Erickson S.R., Kirking D.M. Variation in the distribution of patientreported outcomes based on different definitions of defining asthma severity. Curr. Med. Res. Opin. 2004; 20:1863–1872.

379. Jones P.W. Quality of life measurement in asthma. Eur.Respir. J. 1995; 8: 885–887.

380. Adams R., Wakefield M., Wilson D. et al. Quality of life in asthma: a comparison of community and hospital asthma patients. J. Asthma 2001; 38: 205–214.

381. Chanez P., Wenzel S.E., Anderson G.P. et al. Severe asthma in adults: what are the important questions? J. Allergy Clin. Immunol. 2007; 119: 1337–1348.Buhl R.

382. Buhl R. Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review. Respir. Med.2003; 97: 123–129.

383. Juniper E.F., Jenkins C., Price M.J., James M.H. Impact of inhaled salmeterol / fluticasone propionate combination product versus budesonide on the healthrelated quality of life of patients with asthma. Am. J. Respir. Med.2002; 1:435–440.

384. Cote J., Cartier A., Robichaud P. et al. Influence of asthma education on asthma severity, quality of life and environmental control. Can. Respir. J. 2000; 7: 395–400.

385. Jaeschke R., Singer J., Guyatt G.H.Measurement of health status: ascertaining the minimal clinically important difference. Control. Clin. Trials 1989; 10: 407–415.

386. Jaeschke R., Guyatt G.H., Keller J., Singer J. Interpreting changes in qualityoflife score in N of 1 randomized trials. Control. Clin. Trials 1991; 12: 226S–233S.

387. Schünemann H.J., Puhan M., Goldstein R. et al. Measurement properties and interpretability of the Chronic Respiratory disease Questionnaire (CRQ). COPD 2005; 2:81–89.

388. Schünemann H.J., Guyatt GH. Commentary-goodbye M(C)ID! Hello MID, where do you come from? Hlth Serv. Res. 2005; 40: 593–597.

389. American Thoracic Society. Quality of life resource. 2007 [Accessed June 2008]. Available from: http://www.atsqol.org

390. Ried L.D., Nau D.P., Grainger-Rousseau T.J. Evaluation of patient's Health-Related Quality of Life using a modified and shortened version of the Living With Asthma Questionnaire (ms-LWAQ) and the medical outcomes study,Short-Form 36 (SF-36). Qual. Life Res. 1999; 8: 491–499.

391. Keller S.D., Bayliss M.S., Ware J.E. Jr. et al. Comparison of responses to SF36 Health Survey questions with on-week and four-week recall periods. Hlth Serv. Res. 1997;32: 367–384.

392. Bousquet J., Knani J., Dhivert H. et al. Quality of life in asthma. I. Internal consistency and validity of the SF-36 questionnaire. Am. J. Respir. Crit. Care Med. 1994; 149:371–375.

393. Sato S., Nishimura K., Tsukino M. et al. Possible maximal change in the SF36 of outpatients with chronic obstructive pulmonary disease and asthma. J. Asthma 2004; 41:355–365.

394. Simeoni M.-C., Schmidt S., Muehlan H. et al., Disabkids Group. Field testing of a European quality of life instrument for children and adolescents with chronic conditions: the 37item DISABKIDS Chronic Generic Module. Qual. Life Res. 2007; 16: 881–893.

395. Raat H., Landgraf J.M., Oostenbrink R. et al. Reliability and validity of the Infant and Toddler Quality of Life Questionnaire (ITQQL) in a general population and respiratory disease sample. Qual. Life Res. 2007; 16: 445–460.

396. Carranza Rosenzweig J.R., Edwards L., Lincourt W. et al.The relationship between health-related quality of life,lung function and daily symptoms in patients with persistent asthma. Respir. Med. 2004; 98: 1157–1165.

397. Juniper E.F., Guyatt G.H., Epstein R.S. et al. Evaluation of impairment of health related quality of life in asthma:development of a questionnaire for use in clinical trials.Thorax 1992; 47: 76–83.

398. Juniper E.F., Buist A.S., Cox F.M. et al. Validation of a standardized version of the Asthma Quality of LifeQuestionnaire. Chest 1999; 115: 1265–1270.

399. Juniper E.F., Price D.B., Stampone P.A. et al. Clinically important improvements in asthmaspecific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002; 121: 1824–1832.

400. Juniper E.F., Svensson K., O'Byrne P.M. et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur. Respir. J. 1999; 14:1038–1043.

401. Juniper E.F., Guyatt G.H., Feeny D.H. et al. Measuring quality of life in children with asthma. Qual Life Res.1996;5: 35–46.

402. Juniper E.F., Guyatt G.H., Feeny D.H. et al. Measuring quality of life in the parents of children with asthma. Qual. Life Res. 1996; 5: 27–34.

403. Juniper E.F., Guyatt G.H., Cox F.M. et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur. Respir. J. 1999; 14: 32–38.

404. Marks G.B., Dunn S.M., Woolcock A.J. A scale for the measurement of quality of life in adults with asthma.J. Clin. Epidemiol. 1992; 45: 461–472.

405. Katz P.P., Eisner M.D., Henke J. et al. The Marks Asthma Quality of Life Questionnaire: further validation and examination of responsiveness to change. J. Clin. Epidemiol. 1999; 52: 667–675. [Published erratum appears in J. Clin. Epidemiol. 2001; 54: 106–107; PMID: 11246517].

406. Marks G.B., Dunn S.M., Woolcock A.J. An evaluation of an asthma quality of life questionnaire as a measure of change in adults with asthma. J. Clin. Epidemiol. 1993; 46:1103–1111.

407. Adams R.J., Ruffin R.E., Smith B.J. Validity of a modified version of the Marks Asthma Quality of Life Questionnaire. J. Asthma 2000; 37: 131–143.

408. Hyland M.E. The Living with Asthma Questionnaire.Respir. Med.1991; 85:13–16; discuss. 33–37.

409. Jones P.W., Quirk F.H., Baveystock C.M, Littlejohns P.A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992; 145: 1321–1327.

410. Puhan M.A., Guyatt G.H., Goldstein R. et al. Relative responsiveness of the Chronic Respiratory Questionnaire,St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respir. Med.2007; 101: 308–316.

411. Barley E.A., Jones P.W. A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma. Eur. Respir. J.1999; 14:591–596.

412. Sanjuas C., Alonso J., Prieto L. et al. Health-related quality of life in asthma: a comparison between the St. George's Respiratory Questionnaire and the Asthma Quality of Life Questionnaire. Qual. Life Res. 2002; 11: 729–738.

413. Barley E.A., Quirk F.H., Jones P.W. Asthma health status measurement in clinical practice: validity of a new short and simple instrument. Respir. Med. 1998; 92: 1207–1214.

414. Barley E.A., Jones P.W. Repeatability of a Rasch model of the AQ20 over five assessments. Qual. Life Res. 2006; 15:801–809.

415. Quirk F.H., Jones P.W. Back to basics: how many items can adequately represent health-related QoL in airways disease. Eur. Respir. Rev. 1997; 7: 50–52.

416. Buhl R., Hanf G., Soler M. et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur. Respir. J. 2002; 20:1088–1094.

417. Bateman E.D., Bousquet J., Keech M.L. et al. The correlation between asthma control and health status: the GOAL study. Eur. Respir. J. 2007; 29: 56–62.

418. Dahl R., Gyrd-Hansen D., Kristiansen I.S. et al. Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey. B.M.C. Med. Inform. Decis. Mak. 2007; 7: 8.

419. Woolcock A.J. What are the important questions in the treatment of asthma? Clin. Exp. Allergy. Rev 2001; 1:62–64.


Дополнительные файлы

Для цитирования: Реддел Х.К., Тейлор Д.Р., Бейтман Э.В., Буле Л.-., Буши Г.А., Бюссе В.В., Кэзел Т.Б., Шане П., Энрайт П.Л., Гибсон П.Д., де Жонст Д.С., М.Керстьен Х.А., Лазарус С.С., Леви М.Л., О’Байерн П.М., Партридж М.Р., Паворд И.Д., Сирс М.Р., Стерк П.Д., Столофф С.В., Салливан С.Д., Зефлер С.Д., Томас М.Д., Вензел С.Е. ЛЕЧЕНИЕ БРОНХИАЛЬНОЙ АСТМЫ И ЕЕ ОБОСТРЕНИЙ: СТАНДАРТИЗОВАННЫЕ КОНЕЧНЫЕ ПОКАЗАТЕЛИ ДЛЯ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ ПО АСТМЕ И КЛИНИЧЕСКОЙ ПРАКТИКИ.ОФИЦИАЛЬНЫЙ ДОКУМЕНТ АТО / ЕРО. ЧАСТЬ 2.  Пульмонология. 2011;(2):9-40. https://doi.org/10.18093/0869-0189-2011-0-2-9-40

For citation: Reddel H.K., Taylor D.R., Bateman E.D., Boulet L.-., Boushey Н.A., Busse W.W., Casale T.B., Chanez P., Enright P.L., Gibson P.G., de Jongste J.C., M. Kerstjens H.A., Lazarus S.C., Levy M.L., O’Byrne P.M., Partridge M.R., Pavord I.D., Sears M.R., Sterk P.J., Stoloff S.W., Sullivan S.D., Szefler S.J., Thomas M.D., Wenzel S.E. AN OFFICIAL AMERICAN THORACIC SOCIETY / EUROPEAN RESPIRATORY SOCIETY STATEMENT: ASTHMA CONTROL AND EXACERBATIONS: STANDARDIZING ENDPOINTS FOR CLINICAL ASTHMA TRIALS AND CLINICAL PRACTICE. PART 2. Russian Pulmonology. 2011;(2):9-40. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-2-9-40

Просмотров: 678

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)